Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) is expected to issue its quarterly earnings data on Tuesday, May 13th. Analysts expect the company to announce earnings of $0.48 per share and revenue of $13.39 billion for the quarter.
Bayer Aktiengesellschaft Trading Up 1.6 %
Shares of Bayer Aktiengesellschaft stock traded up $0.11 on Tuesday, reaching $6.85. 364,915 shares of the company were exchanged, compared to its average volume of 828,004. The company has a current ratio of 1.32, a quick ratio of 0.81 and a debt-to-equity ratio of 1.19. Bayer Aktiengesellschaft has a fifty-two week low of $4.79 and a fifty-two week high of $8.58. The firm has a market capitalization of $26.92 billion, a price-to-earnings ratio of -26.35 and a beta of 0.84. The stock has a fifty day moving average price of $6.18 and a 200-day moving average price of $5.78.
Bayer Aktiengesellschaft Increases Dividend
The company also recently disclosed a dividend, which will be paid on Monday, May 12th. Shareholders of record on Wednesday, April 30th will be paid a dividend of $0.0224 per share. The ex-dividend date is Tuesday, April 29th. This is a positive change from Bayer Aktiengesellschaft's previous dividend of $0.02. This represents a yield of 0.38%. Bayer Aktiengesellschaft's dividend payout ratio is currently -2.78%.
Wall Street Analyst Weigh In
Separately, Hsbc Global Res raised shares of Bayer Aktiengesellschaft to a "hold" rating in a research note on Monday, April 28th.
Get Our Latest Report on Bayer Aktiengesellschaft
About Bayer Aktiengesellschaft
(
Get Free Report)
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Bayer Aktiengesellschaft, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bayer Aktiengesellschaft wasn't on the list.
While Bayer Aktiengesellschaft currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
